---
schema_version: "secwatch.filing_event.v1"
accession: "0001746473-23-000007"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T07:17:55.402312+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Pliant reports Q4 2022 net loss $35.1M; positive bexotegrast data, $287.5M raise extends runway to H2 2026

## Summary
- Bexotegrast 320 mg in IPF Phase 2a showed statistically significant FVC increases at 12 weeks; no drug-related severe AEs.
- Closed $287.5M equity offering in Jan 2023; net proceeds $269.9M, extending cash runway into second half of 2026.
- Q4 2022 net loss $35.1M ($24.5M prior year); R&D expenses $25.1M, G&A $14.3M.
- 24-week INTEGRIS-IPF 320 mg data expected Q2 2023; Phase 2b IPF trial initiation mid-2023.
- EMA granted Orphan Drug designation for bexotegrast in IPF; Novartis terminated PLN-1474 deal and returned rights.

## SEC filing metadata
- accession: 0001746473-23-000007
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000174647323000007/0001746473-23-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000174647323000007/plrx-20230309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001746473-23-000007
- JSON: https://secwatch.observer/filing/0001746473-23-000007.json
- Plain text: https://secwatch.observer/filing/0001746473-23-000007.txt

## Key facts
- Earnings Releases
  PLIANT THERAPEUTICS, INC. reported financial results for the fourth quarter ended December 31, 2022.
  - Period: the fourth quarter ended December 31, 2022
  - Result: reported results
  source text: On March 9, 2023, Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company’s financial results for the fourth quarter ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1746473/000174647323000007/0001746473-23-000007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.